42191-48-0

Usage

Uses

Used in Pharmaceutical Development:
2-(3,4-Dimethoxy-phenyl)-N-hydroxy-acetamidine is used as a potential drug candidate for the treatment of various diseases due to its pharmacological properties. Its specific applications in medicine are yet to be fully explored, but its unique structure suggests it may have therapeutic relevance in multiple areas of healthcare.
Used in Organic Synthesis:
In the field of organic synthesis, 2-(3,4-Dimethoxy-phenyl)-N-hydroxy-acetamidine serves as a valuable intermediate or building block for the synthesis of more complex organic compounds. Its reactivity and functional groups make it a useful component in the creation of novel organic molecules with potential applications in various industries.
Used in Chemical Research:
As a chemical research tool, 2-(3,4-Dimethoxy-phenyl)-N-hydroxy-acetamidine aids scientists in understanding the fundamental chemical reactions and mechanisms that occur within its structure. It can be employed to study reaction kinetics, explore new synthetic pathways, and investigate the properties of related compounds.
Further research and studies are necessary to fully elucidate the potential uses and applications of 2-(3,4-Dimethoxy-phenyl)-N-hydroxy-acetamidine across different industries and scientific disciplines.

Upstream product

• 93-17-4 3,4-dimethoxyphenylacetonitrile 

Downstream Products

• 1235444-12-8 N'-(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-ylcarbonyloxy)-(3,4-dimethoxyphenyl)acetimidamide 
• 757878-04-9 2-(3,4-dimethoxy-phenyl)-acetamidine 

Relevant academic research and scientific papers

NOVEL COMPOUNDS AND THEIR USE IN THERAPY

The invention provides compounds which inhibit N-myristoyltransferase and are selective for protozoal N-myristoyltransferase and, consequently suitable to treat microbial infections, including viral and fungal infections, and protozoan infections such as malaria, leishmaniasis and sleeping sickness.

Dihydroxypyrimidine-4-carboxamides as novel potent and selective HIV integrase inhibitors

Human immunodeficiency virus type-1 (HIV-1) integrase, one of the three constitutive viral enzymes required for replication, is a rational target for chemotherapeutic intervention in the treatment of AIDS that has also recently been confirmed in the clinical setting. We report here on the design and synthesis of N-benzyl-5,6-dihydroxypyrimidine-4-carboxamides as a class of agents which exhibits potent inhibition of the HIV-integrase-catalyzed strand transfer process. In the current study, structural modifications on these molecules were made in order to examine effects on HIV-integrase inhibitory potencies. One of the most interesting compounds for this series is 2-[1-(dimethylamino)-1-methylethyl]-N-(4-fluorobenzyl)-5,6-dihydroxypyrimidine- 4-carboxamide 38, with a CIC95 of 78 nM in the cell-based assay in the presence of serum proteins. The compound has favorable pharmacokinetic properties in preclinical species (rats, dogs, and monkeys) and shows no liabilities in several counterscreening assays, highlighting its potential as a clinically useful antiviral agent.

New O-(3-amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same

A compound effective in the treatment of diabetic angiopathy, i.e. a selective β-receptor blocker has the formula STR1 wherein: R2 is a hydrogen or alkyl having one to five carbon atoms, R3 is alkyl having one to five carbon atoms, cycloalkyl or phenyl optionally substituted with hydroxyl or phenyl, or R2 and R3 together form a five- to eight-membered ring optionally containing also other heteroatoms and/or fused with an other ring, preferably phenyl, naphthyl, quinolyl, isoquinolyl, pyridyl, pyrazolyl, R5 is hydrogen or alkyl having one to four carbon atoms, cycloalkyl or phenyl optionally substituted with halogen, alkoxy having one to four carbon atoms or alkyl having one to four carbon atoms, R6 is hydrogen, alkyl having one to four carbon atoms or phenyl, m=0, 1 or 2, and n=0, 1 or 2.